
PaySign Inc (PAYS) Stock Forecast & Price Target
PaySign Inc (PAYS) Analyst Ratings
Bulls say
PaySign Inc. is projected to achieve a 26% year-over-year increase in total revenue for 2025, reaching $73.4 million, supported by significant growth across its diverse service offerings. The company is also expected to experience a remarkable 72% year-over-year growth in adjusted EBITDA, forecasted at $16.6 million, with margins anticipated to expand by 610 basis points to 22.6%. Additionally, the strong performance in the Pharma segment is expected to contribute to adjusted EBITDA margins that may rise between 570 and 650 basis points, further solidifying the financial outlook for the company.
Bears say
PaySign Inc. experienced a significant decline in revenue within the Plasma Donor Compensation segment, posting a 9% year-over-year decrease to $9.4 million, which fell short of forecasts by $0.5 million. This downturn can be attributed to an oversupply of plasma in the U.S., exacerbated by new extraction techniques that enable higher plasma yield per donation, leading collection centers to reduce compensation for donors. Furthermore, the company faced a more extensive financial setback in 2020, with total revenue plunging 30% year-over-year to $24 million and adjusted EBITDA deteriorating to a loss of $2.8 million, down from a positive $10.1 million in 2019.
This aggregate rating is based on analysts' research of PaySign Inc and is not a guaranteed prediction by Public.com or investment advice.
PaySign Inc (PAYS) Analyst Forecast & Price Prediction
Start investing in PaySign Inc (PAYS)
Order type
Buy in
Order amount
Est. shares
0 shares